Shares of ChemoCentryx Inc. (NASDAQ:CCXI) were down 3.9% during mid-day trading on Monday . The stock traded as low as $4.42 and last traded at $4.45, with a volume of 62,528 shares trading hands. The stock had previously closed at $4.63.

Several analysts have issued reports on CCXI shares. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Wednesday, April 27th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The stock’s market capitalization is $197.09 million. The firm has a 50 day moving average price of $4.79 and a 200-day moving average price of $3.74.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.07. Equities research analysts predict that ChemoCentryx Inc. will post ($0.35) EPS for the current year.

In other news, Director Geoffrey M. Parker acquired 40,000 shares of the company’s stock in a transaction on Friday, May 13th. The shares were bought at an average cost of $4.03 per share, with a total value of $161,200.00. Following the purchase, the director now owns 13,514 shares of the company’s stock, valued at approximately $54,461.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas A. Edwards acquired 25,000 shares of the company’s stock in a transaction on Monday, May 16th. The stock was purchased at an average cost of $4.05 per share, for a total transaction of $101,250.00. Following the completion of the purchase, the director now directly owns 41,977 shares in the company, valued at approximately $170,006.85. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in ChemoCentryx stock. Westfield Capital Management Co. LP boosted its stake in shares of ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned about 2.50% of ChemoCentryx worth $8,929,000 at the end of the most recent quarter.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.